Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Exploring Tykerb Potential In Patients Not Previously Treated With Herceptin

This article was originally published in The Pink Sheet Daily

Executive Summary

Subset of breast cancer patients given lapatinib plus paclitaxel first line shows significant advantage in progression-free survival, duration of response.

You may also be interested in...



FDA Calls GlaxoSmithKline Professional Mailers For Tykerb “Misleading”

GSK shares FDA’s concerns, but says the promos were accompanied by full prescribing information, firm tells “The Pink Sheet” DAILY.

FDA Calls GlaxoSmithKline Professional Mailers For Tykerb “Misleading”

GSK shares FDA’s concerns, but says the promos were accompanied by full prescribing information, firm tells “The Pink Sheet” DAILY.

GSK Tykerb Opportunities Exist In Early Breast Cancer Setting – Oncologist

As many as 10 percent of early-stage HER2 positive breast cancer patients, who are not ideal candidates for Herceptin, could be candidates for Tykerb, oncologist Ellis estimates.

Related Content

Topics

UsernamePublicRestriction

Register

PS066265

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel